Valneva Races Ahead in Stock Market Even as Vaccine Lags Behind

This article was originally published on this site

[unable to retrieve full-text content]French biotechnology company Valneva SE is a laggard in the race to develop a coronavirus vaccine, but it’s starting to catch up to peers in the stock market after a 56% jump this year.